MarketPulse

pevifoscorvir sodium

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Aligos Therapeutics, Inc.

Aligos Therapeutics Cuts Losses 82% While Advancing Hepatitis B Pipeline

Aligos reports $24.2M net loss in 2025, down 82% YoY. Key hepatitis B study enrollment complete; cash runway extends to Q3 2026.
ALGSPhase 2 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Aligos Presents Clinical Advances in Hepatitis B and Coronavirus Inhibitor Programs

Aligos presented clinical progress for hepatitis B and coronavirus treatments at CROI. Pevifoscorvir showed strong viral suppression, while ALG-097558 provided dosing data for impaired patients.
ALGSclinical trialhepatitis B virus (HBV)